Blockade of OX40/OX40 ligand to decrease cytokine messenger RNA expression in acute renal allograft rejection in...

Area of Science:

• Immunology
• Transplantation Biology
• Molecular Medicine

Background:

• Acute rejection remains a significant challenge in renal transplantation.
• Cytokine production by peripheral blood mononuclear cells (PBMCs) plays a crucial role in transplant rejection.
• The OX40-OX40L pathway is implicated in T-cell activation and immune responses.

Purpose of the Study:

• To investigate the effect of blocking OX40-OX40L interactions on cytokine mRNA expression in renal transplant recipients with acute rejection.
• To evaluate the potential of recombinant human OX40-Fc fusion protein (rhOX40Fc) as a therapeutic agent in vitro.

Main Methods:

• PBMCs were isolated from renal transplant recipients experiencing acute rejection (rejection group) and those with stable graft function (stable group).
• Messenger RNA (mRNA) expression levels of Th1 (interferon-gamma [IFN-γ]) and Th2 (interleukin-4 [IL-4]) cytokines were quantified using real-time reverse transcriptase-polymerase chain reactions.
• The impact of rhOX40Fc on cytokine mRNA expression was assessed in anti-CD3-monoclonal antibody stimulated PBMCs from the rejection group.

Main Results:

• IFN-γ mRNA expression was significantly higher in the rejection group compared to the stable group (P < .05).
• IL-4 mRNA expression levels did not differ significantly between the groups.
• In the rejection group, rhOX40Fc treatment significantly reduced both IFN-γ and IL-4 mRNA expression (P < .05 and P < .01, respectively).

Conclusions:

• In vitro blockade of OX40-OX40L interaction effectively inhibited the production of Th1 and Th2 type cytokines.
• These findings highlight the potential of targeting the OX40-OX40L pathway to modulate immune responses in renal transplant rejection.